Modified Kozak Sequences for rAAV Capsid Stoichiometry Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of recombinant adeno-associated virus (rAAV) in insect cells faces challenges due to altered AAV capsid stoichiometry, leading to lower biological potency and inefficient transduction, as the stochastic assembly of capsid proteins VP1, VP2, and VP3 results in improper protein ratios, affecting the ability to produce high-yield, infective particles.
Innovation Solution
The use of recombinant VP1, VP2, or VP3 genes with modified Kozak sequences to control the translation initiation site, combined with a combinatorial capsid library screening protocol, allows for the identification of capsid variants with enhanced infectivity and transduction efficiency by optimizing the VP1:VP2:VP3 ratio through directed evolution and Next-Generation Sequencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV production is performed in insect cells, then scalability and production yield are improved, but capsid stoichiometry is altered resulting in lower biological potency
Solution Approach 1:
The patent modifies the Kozak sequence parameters of the VP1 gene to change translation initiation efficiency. By altering specific nucleotide sequences in the Kozak region (GCCACC to GCCCGC), the patent adjusts VP1 protein expression levels to achieve optimal capsid stoichiometry while maintaining high production yield in insect cells.
Solution Approach 2:
The patent introduces a tunable Kozak sequence that can be dynamically adjusted to control VP1 expression levels. This dynamic control allows optimization of capsid assembly stoichiometry in response to different production conditions, enabling both high yield and high biological potency.
2Productivity
If VP1 expression is increased to improve capsid assembly, then particle production is enhanced, but transduction efficiency decreases due to improper capsid composition
Solution Approach 1:
The patent precisely adjusts the VP1 expression parameter by modifying the Kozak sequence strength. The modified Kozak sequence (GCCCGC) provides enhanced translation initiation compared to wild-type, but this is balanced by the natural stoichiometric constraints of capsid assembly, resulting in optimal VP1:VP2:VP3 ratios that maintain high transduction efficiency.
3Reliability
If VP1 expression is decreased to improve transduction efficiency, then particle infectivity is improved, but capsid assembly is impaired reducing production yield
Solution Approach 1:
The patent optimizes the VP1 expression parameter by using a modified Kozak sequence that provides just the right amount of translation initiation. The GCCCGC sequence creates a balanced expression level that ensures sufficient capsid assembly while maintaining the ability to form infectious particles with high transduction efficiency.
Data Source
AI summary
Provided herein are methods and compositions useful in the screening and production of recombinant AAV (rAAV) that have structural fitness and potency in insect cells and mammalian cells. The disclosure provides a directed evolution system for generating and selecting rAAV variants based on their Kozak sequences. In some embodiments, methods disclosed herein comprise the use of modified Kozak sequences to express AAV2 VP1 proteins in amounts that are useful for producing rAAV particles having high infectivities and/or transduction efficiencies. In some embodiments, methods of producing, and methods of screening, rAAV are provided that comprise the steps of infecting insect cells by administering rAAV to these cells, recovering rAAV-integrated DNA from these insect cells, and transfecting recovered rAAV into mammalian cells. Also provided herein are nucleic acids comprising nucleotide sequences encoding novel Kozak sequences. Further provided herein are mammalian cells, baculovirus particles and insect cells comprising these nucleic acids.